NIKKEI 225
38,719.35 -227.58 (-0.58%) HANG SENG
19,286.37 +65.75 (+0.34%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,421.80 -4.10 (-0.17%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,011.90 -1,015.38 (-1.81%)
CRBU Jul 2024 2.500 put
| Previous close | 0.1500 |
| Open | 0.2200 |
| Bid | 0.0000 |
| Ask | 0.5500 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.2200 - 0.2200 |
| Contract range | N/A |
| Volume | |
| Open interest | 53 |
Simply Wall St.Caribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are probably feeling a little disappointed, since its shares...
ZacksCaribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCaribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash
